La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Incyte Gestion

Gestion contrôle des critères 4/4

Le PDG Incyte's est Herve Hoppenot, nommé en Jan2014, a un mandat de 10.58 ans. La rémunération annuelle totale est $ 16.66M, composée du salaire de 7.8% et des bonus 92.2%, y compris les actions et options de la société. détient directement 0.2% des actions de la société, d'une valeur de $ 23.74M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 8.6 ans et 7.6 ans.

Informations clés

Herve Hoppenot

Directeur général

US$16.7m

Rémunération totale

Pourcentage du salaire du PDG	7.8%
Durée du mandat du directeur général	10.7yrs
Propriété du PDG	0.2%
Durée moyenne d'occupation des postes de direction	8.7yrs
Durée moyenne du mandat des membres du conseil d'administration	7.7yrs

Mises à jour récentes de la gestion

Recent updates

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Aug 19

Incyte: The Worst Has Been Avoided

Jun 16

It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

Jun 06

Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia

Sep 15

Incyte wins approval of Pemazyre for rare blood cancer

Aug 26

Incyte Q2 results beat on top and bottom lines as net income soars 27%; shares down 6%

Aug 02

With EPS Growth And More, Incyte (NASDAQ:INCY) Makes An Interesting Case

Jul 27

Incyte Corp. Should Move Higher (Technical Analysis)

Jul 18

Incyte: Growth Drivers Are Coming

Jun 17

Incyte Is A Buy As Ruxolitinib Ramps Revenue And Pipeline Matures

Apr 14

Analyse de la rémunération des PDG

Comment la rémunération de Herve Hoppenot a-t-elle évolué par rapport aux bénéfices de Incyte?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	US$97m
Mar 31 2024	n/a	n/a	US$745m
Dec 31 2023	US$17m	US$1m	US$598m
Sep 30 2023	n/a	n/a	US$425m
Jun 30 2023	n/a	n/a	US$366m
Mar 31 2023	n/a	n/a	US$324m
Dec 31 2022	US$17m	US$1m	US$341m
Sep 30 2022	n/a	n/a	US$876m
Jun 30 2022	n/a	n/a	US$945m
Mar 31 2022	n/a	n/a	US$933m
Dec 31 2021	US$14m	US$1m	US$949m
Sep 30 2021	n/a	n/a	US$535m
Jun 30 2021	n/a	n/a	US$338m
Mar 31 2021	n/a	n/a	US$478m
Dec 31 2020	US$16m	US$1m	-US$296m
Sep 30 2020	n/a	n/a	-US$335m
Jun 30 2020	n/a	n/a	-US$191m
Mar 31 2020	n/a	n/a	-US$376m
Dec 31 2019	US$15m	US$1m	US$447m
Sep 30 2019	n/a	n/a	US$405m
Jun 30 2019	n/a	n/a	US$306m
Mar 31 2019	n/a	n/a	US$253m
Dec 31 2018	US$9m	US$996k	US$109m
Sep 30 2018	n/a	n/a	-US$109m
Jun 30 2018	n/a	n/a	-US$102m
Mar 31 2018	n/a	n/a	-US$167m
Dec 31 2017	US$16m	US$967k	-US$313m

Rémunération vs marché: La rémunération totale de Herve ($USD 16.66M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 13.21M ).

Rémunération et revenus: La rémunération de Herve a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Herve Hoppenot (64 yo)

10.7yrs

Titularisation

US$16,659,526

Compensation

Mr. Herve Hoppenot has been the Chairman of the Board at Incyte Corporation since May 2015 and as its Chief Executive Officer and was President since January 13, 2014 until June 05, 2023. Mr. Hoppenot serv...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Herve Hoppenot	CEO & Chairman	10.7yrs	US$16.66m	0.20% $ 25.1m
Pablo Cagnoni	President and Head of Research & Development	1.3yrs	US$16.57m	0.00087% $ 110.3k
Christiana Stamoulis	Executive VP & CFO	5.6yrs	US$5.08m	0.019% $ 2.4m
Barry Flannelly	Executive VP & GM of North America	9.3yrs	US$4.09m	0.0062% $ 786.1k
Steven Stein	Executive VP & Chief Medical Officer	9.5yrs	US$5.63m	0.0013% $ 168.6k
Thomas Tray	VP of Finance	2.5yrs	pas de données	0.0047% $ 594.6k
Michael Morrissey	Executive VP & Head of Global Technical Operations	8.7yrs	pas de données	0.019% $ 2.4m
Ben Strain	Head of Investor Relations	no data	pas de données	pas de données
Sheila Denton	Executive VP	less than a year	pas de données	pas de données
Pamela Murphy	Vice President of Investor Relations & Corporate Communications	no data	pas de données	pas de données
Paula Swain	Executive Vice President of Human Resources	22.1yrs	US$1.31m	0.030% $ 3.8m
Vijay Iyengar	Executive VP of Global Medical Affairs	no data	US$3.30m	0.0044% $ 559.1k

8.7yrs

Durée moyenne de l'emploi

60yo

Âge moyen

Gestion expérimentée: L'équipe de direction de INCY est chevronnée et expérimentée (ancienneté moyenne 8.6 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Herve Hoppenot	CEO & Chairman	10.7yrs	US$16.66m	0.20% $ 25.1m
Jean-Jacques Bienaime	Independent Director	9.7yrs	US$478.76k	0.0080% $ 1.0m
Julian Baker	Independent Lead Director	22.8yrs	US$512.76k	0.14% $ 18.4m
Otis Brawley	Independent Director	3yrs	US$454.76k	0.0031% $ 389.2k
Jacqualyn Fouse	Independent Director	7.7yrs	US$466.26k	0.0073% $ 920.5k
Edmund Harrigan	Independent Director	4.8yrs	US$482.26k	0.0070% $ 890.0k
Katherine High	Independent Director	4.5yrs	US$454.76k	0.0042% $ 526.2k
Paul Clancy	Independent Director	9.7yrs	US$479.76k	0.0084% $ 1.1m
Susanne Schaffert	Independent Director	1.9yrs	US$444.76k	0.0015% $ 190.2k

7.7yrs

Durée moyenne de l'emploi

64yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de INCY sont considérés comme expérimentés (ancienneté moyenne 7.6 ans).

Incyte Gestion

Gestion contrôle des critères 4/4

Informations clés

Mises à jour récentes de la gestion

Executive VP & Chief Medical Officer recently sold US$704k worth of stock

Executive VP & Chief Medical Officer notifies of intention to sell stock

Executive VP of Global Medical Affairs recently sold US$1.1m worth of stock

Executive VP of Global Medical Affairs notifies of intention to sell stock

Executive VP & GM of North America recently sold US$1.1m worth of stock

Executive VP & GM of North America notifies of intention to sell stock

Recent updates

Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

Executive VP & Chief Medical Officer recently sold US$704k worth of stock

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Executive VP & Chief Medical Officer notifies of intention to sell stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP of Global Medical Affairs recently sold US$1.1m worth of stock

Consensus EPS estimates fall by 74%

Executive VP of Global Medical Affairs notifies of intention to sell stock

Incyte Corporation to Report Q2, 2024 Results on Jul 30, 2024

Incyte: The Worst Has Been Avoided

Executive VP & GM of North America recently sold US$1.1m worth of stock

Executive VP & GM of North America notifies of intention to sell stock

It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year

Incyte Corporation (NasdaqGS:INCY) acquired Escient Pharmaceuticals, Inc. from a group of shareholders.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings

Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Maintains Earnings Guidance for 2024

Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.

Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024

Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)

Incyte: A Potential GARP Superstar

Incyte Corporation Provides Earnings Guidance for 2024

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Incyte Corporation to Report Q4, 2023 Results on Feb 13, 2024

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Incyte Corporation Provides Earning Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Incyte Corporation to Report Q3, 2023 Results on Oct 31, 2023

Incyte Corporation Announces Executive Changes, Effective November 1, 2023

Executive VP & Chief Medical Officer recently sold US$1.4m worth of stock

Executive VP & Chief Medical Officer notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Incyte Corporation Revises Earnings Guidance for the Year 2023

Consensus EPS estimates increase by 21%

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Incyte Corporation to Report Q2, 2023 Final Results on Aug 01, 2023

Price target decreased by 7.5% to US$82.42

Incyte Corporation Appoints Pablo J. Cagnoni, M.D. as President and Head of Research & Development, Effective June 5, 2023

Consensus EPS estimates fall by 12%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Executive VP & Chief Scientific Officer exercised options to buy US$287k worth of stock.

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

Incyte Corporation Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Insider exercised options and sold US$115k worth of stock

Incyte Corporation to Report Q4, 2022 Results on Feb 07, 2023

Executive VP & Chief Medical Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today

Incyte Corporation Announces Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine

Incyte Corporation to Report Q3, 2022 Results on Nov 01, 2022

Knight's affiliate files for Brazilian approval of cancer drug tafasitamab

Incyte Announces the Appointment of Susanne Schaffert as New Member of Its Board of Directors

Incyte Corporation (NasdaqGS:INCY) entered into an agreement to acquire Villaris Therapeutics, Inc. from Medicxi Ventures (UK) LLP and others for $1.4 billion.

Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart

Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia